학술논문

Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki‐67 Is ≥10%?
Document Type
Article
Source
Oncologist; Apr2021, Vol. 26 Issue 4, p294-301, 8p, 2 Charts, 3 Graphs
Subject
THERAPEUTIC use of antineoplastic agents
PANCREATIC tumors
RESEARCH
ACQUISITION of data methodology
CONFIDENCE intervals
NUCLEAR proteins
TIME
RETROSPECTIVE studies
MEDICAL cooperation
TREATMENT effectiveness
CANCER patients
NEUROENDOCRINE tumors
SOMATOSTATIN
MEDICAL records
SURVIVAL analysis (Biometry)
DESCRIPTIVE statistics
TUMOR antigens
TUMOR markers
PATIENT safety
EVALUATION
Language
ISSN
10837159
Abstract
Copyright of Oncologist is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)